A.J. Grillo-López - Concepedia

Author

A.J. Grillo-López

Roswell Park Comprehensive Cancer Center

Also Known As

A Grillo-Lopez, A Grillo-López, A J Grillo-Lopez, A J Grillo-López, A. Grillo-Lopez, A. Grillo-López, A. J. Grillo-Lopez, A. J. Grillo-López, A. J. Grillo‐López, A.J Grillo-López

Publications

8.9K

Citations

H-Index

Concepts

All Affiliations

Roswell Park Comprehensive Cancer Center The University of Texas MD Anderson Cancer Center Stanford University Fred Hutch Cancer Center Amsterdam UMC Location University of Amsterdam

About

A.J. Grillo-López is an author at Roswell Park Comprehensive Cancer Center specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	2.1K
2	Immunology	10	10	1.9K
3	Health Sciences	3	3	436
4	Biomolecular Engineering	1	1	31
5	Biostatistics	1	1	78

A.J. Grillo-López

Publications

8.4K

Citations

H-Index

Page 1

	Year	Citations
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Peter McLaughlin, A.J. Grillo-López, Brian K. Link, Journal of Clinical Oncology	1998	2.8K
Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy M. S. Czuczman, A.J. Grillo-López, Christine A. White, Journal of Clinical Oncology	1999	855
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma DG Maloney, TM Liles, DK Czerwinski, Blood	1994	747
IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. DG Maloney, A.J. Grillo-López, David Bodkin, Journal of Clinical Oncology	1997	636
Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma Neil L. Berinstein, A.J. Grillo-López, Christine A. White, Annals of Oncology Anti-tumor ResponseLymphoid NeoplasiaHematological MalignancySerum RituximabMedicine	1998	520
Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s Lymphoma Julie M. Vose, Brian K. Link, Michael L. Grossbard, Journal of Clinical Oncology	2001	416
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma Lawrence D. Piro, Christine A. White, A.J. Grillo-López, Annals of Oncology Lymphoid NeoplasiaMedicineImmunologyAnti-cd20 Monoclonal AntibodyImmune Checkpoint Inhibitor	1999	368
Complement activation plays a key role in the side‐effects of rituximab treatment Lizet E. van der Kolk, A.J. Grillo-López, Joke W. Baars, British Journal of Haematology Key RoleImmunologyPathologyPharmacotherapyImmunotherapy	2001	322
Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. A.J. Grillo-López, Christine A. White, C. Varns, PubMed	1999	294
Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab Thomas A. Davis, Christine A. White, A.J. Grillo-López, Journal of Clinical Oncology ImmunologyImmunotherapyHematological MalignancyOncologyHematology	1999	289

Page 1